Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now
2026-03-03 09:50:00 ET
Broader equities have been relatively volatile over the past few months. In an environment like this, it's best to prioritize investing in well-established, profitable corporations. While small-cap stocks may have higher upside potential than much larger companies, the risks they entail often make them not worth investing in.
With that as a backdrop, let's consider one smaller company that has performed pretty well over the trailing-12-month period, but isn't worth your time: Amarin (NASDAQ: AMRN) . Instead of betting on this small drugmaker, it's best to put your hard-earned money into a pharmaceutical leader like Novartis (NYSE: NVS) instead.
Image source: Getty Images.
NASDAQ: NVS
NVS Trading
-0.41% G/L:
$159.175 Last:
2,310,454 Volume:
$156.71 Open:
